Merck is making a $125 million investment in Moderna as part of a new funding round. "We’re encourage by the potential for RNA-based vaccines," says Eric Rubin, a Merck vice president.
Teva is expected to report earnings of $0.66 per share on $4.80 billion in revenue. Meanwhile, the so-called Whisper number is $0.70.
The real pressure caused by the presumed overabundance of cancer research falls on investors and decision makers who guide R&D portfolios.
Another study combined Opdivo and Yervoy, two drugs made by Bristol-Myers Squibb, in lung cancer patients selected with a new type of diagnostic test. An third result hints that giving Opdivo earlier – before surgery to remove tumors – may lead to even more benefits for patients.
What if Keytruda and Opdivo, the new lung cancer drugs, are as good as it gets? How long will it be before anyone invents medicines that are any better than what we now have?